Presentation on theme: "March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Patient Registries and Participating in Clinical Trials Susan L. Perlman M.D. Clinical Professor."— Presentation transcript:
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Patient Registries and Participating in Clinical Trials Susan L. Perlman M.D. Clinical Professor of Neurology Director, UCLA Ataxia Center Medical Director, NAF
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together The Bottom Line Every ataxia patient must participate in clinical trials. Every researcher designing a clinical trial must make it accessible to all ataxia patients. There will be exceptions to both of these fiats, but they must be justified.
TYPES OF CLINICAL TRIALS TYPE # SUBJECTSLENGTHAIM OF STUDY N of 1 1OngoingDo I get better or stop getting worse on this drug? Pilot Up to 20 All get drug Weeks to months Is a larger study worth doing, will there be problems? Phase normal or patient in groups of 3 All get drug 2 yearsEscalating doses to learn side effects, safety, best dose Phase Placebo and drug groups Compassionate trials do not use placebo. 2 yearsTo assess potential for good effects, as well as side effects. Also designed as “futility” study—to show a drug doesn’t not work(fewer subjects, less$) Phase Placebo and drug groups 3-5 yearsTo prove efficacy May include crossover design, open extension trial Phase 4 100’s-1000’s Open drug use OngoingTo find out more about the effects of an approved drug.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Every Ataxia Patient Must Participate in Clinical Trials 1.Registries will enable you to be found. These are rare diseases with very small numbers of patients who can participate. Every person counts. 2. Be knowledgeable about what makes a good clinical trial—don’t make bad investments. 3.Speak up about the roadblocks to participation. Become involved in planning the trials. 4.Be prepared to make sacrifices.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Every Researcher Designing A Clinical Trial Must Make It Accessible To All Ataxia Patients. Design trials that can use the fewest patients over the shortest period of time (this usually means testing better drugs and using biomarkers). What is the rationale for excluding certain patients? Can those excluded be used in other ways? Parallel or compassionate studies? But remember that a patient can participate in only one trial at a time and that participation in some trials may permanently disqualify participation in others. Reimbursing travel costs is essential for recruitment and compliance. Telemedicine? Don’t expect the patients to make unreasonable sacrifices.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Registries Ataxia patients are some of the most highly motivated research subjects around, but they aren’t superhuman. The Cooperative Ataxia Research Network and the National Ataxia Foundation are not mind-readers. Every ataxia patient must be in a Registry.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together The National Ataxia Registry for all ataxias, must sign a consent form and provide PHI National Ataxia Registry C/o Registry Coordinator Department of Neurology McKnight Brain Institute at University of Florida 100 S. Newell Dr. L1-108 PO Box Gainesville, FL Phone : Fax: Web Site: Has links to all the other registries.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Rare Diseases Clinical Research Network Registry for all ataxias participants in the Clinical Research Consortium for SCA 1, 2, 3, and 6 are automatically registered After you have read and agreed to the authorization, the Contact Registry form will appear on your screen. This form asks you for information such as your (or your child's) name, address, birth date, place of birth, address, or items relevant to your (or your child's) disorders: Ataxia telangiectasia Ataxia with oculomotor apraxia (AOA) type 1 Ataxia with oculomotor apraxia (AOA) type 2 Ataxia with vitamin E deficiency (AVED) Ataxia, unknown cause Autosomal recessive ataxia of Charlevoix-Saguenay (ARSACS) Dentatorubral-pallidoluysian atrophy (DRPLA) Fragile X tremor-ataxia syndrome (FXTAS) Friedreich's ataxia GAD ataxia Gluten ataxia Mitochondrial ataxia Mitochondrial recessive ataxia syndrome (MIRAS; POLG mutation) Multiple system atrophy-cerebellar type (MSA-C) Olivopontocerebellar atrophy (OPCA) Paraneoplastic ataxia Spinocerebellar ataxia 1(SCA1) Spinocerebellar ataxia 2(SCA2) Spinocerebellar ataxia 3(SCA3/Machado Joseph disease/MJD) Spinocerebellar ataxia 4(SCA4) Spinocerebellar ataxia 5(SCA5) Spinocerebellar ataxia 6(SCA6) Spinocerebellar ataxia 7(SCA7) Spinocerebellar ataxia 8(SCA8) Spinocerebellar ataxia 10(SCA10) Spinocerebellar ataxia 11(SCA11) Spinocerebellar ataxia 12(SCA12) Spinocerebellar ataxia 13(SCA13) Spinocerebellar ataxia 14(SCA14) Spinocerebellar ataxia 15(SCA15) Spinocerebellar ataxia 16(SCA16) Spinocerebellar ataxia 17(SCA17) Spinocerebellar ataxia 18(SCA18) Spinocerebellar ataxia 19(SCA19) Spinocerebellar ataxia 20(SCA20) Spinocerebellar ataxia 21(SCA21) Spinocerebellar ataxia 22(SCA22) Spinocerebellar ataxia 23(SCA23) Spinocerebellar ataxia 24(SCA24); Spinocerebellar Ataxia, Autosomal Recessive 4; SCAR4 Spinocerebellar ataxia 25(SCA25) Spinocerebellar ataxia 26(SCA26) Spinocerebellar ataxia 27(SCA27) Spinocerebellar ataxia 28(SCA28) Spinocerebellar ataxia 29(SCA29) Spinocerebellar ataxia 31(SCA31) Sporadic ataxia (onset before 20 years) Sporadic ataxia (onset between years) Sporadic ataxia (onset after 50 years)
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together CINCH for episodic ataxias CINCH Clinical Investigation of Neurologic Channelopathies is a collaborative effort of doctors, patient organizations, and federal health agencies that want to learn more about these diseases so that ultimately they can offer better treatments to patients.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Friedreich’s Ataxia Registry The FARA patient registry is the only worldwide registry of Friedreich’s ataxia patients. This registry currently holds the demographic and clinical information on >1200 Friedreich’s ataxia patients from across the United States and internationally. This registry was created to serve the patient, physician, and research communities. For the Patient Community Participation in the FARA patient registry ensures that patients are informed about opportunities to participate in clinical research studies and kept up-to-date on the progress of clinical trials. For the Physician The homepage of the FARA patient registry website, is a place that you can go to find an up-to-date listing of ongoing clinical trials for FA. You can refer your FA patients to the patient registry so that he/she can consider registering. FARA can provide you with registry brochures that you can give your patients to assist with the referral process.www.curefa.org/registry For the Researcher The FARA patient registry is a patient recruitment and communications tool for both academic and industry sponsored clinical research studies and trials. The registry coordinator can perform queries based on the inclusion/ exclusion criteria of a study and send patients information about a study for which they qualify. Patients can be contacted by the registry coordinator via , mail, or by telephone. Informational postings can also be added to the registry homepage as well as the FARA website and in the FARA newsletter. FARA is committed to assisting researchers with study recruitment and participation.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Becoming A Knowledgeable Consumer General trial info: Determining dosage maximum – is it safe? How will my confidentiality be maintained? Identity disclosure issues Explain need for exclusionary and placebo process How to choose a trial and where to go Telemedicine for trials? Face to face presentation of each trial’s process/benefit and communicate to potential participants: Why do we have to discontinue our current meds? What are the measures of confidentiality required or available? Type of contact? In terms of ongoing trials: Why is this trial being done? What’s the long term benefit? Explain what you’ll do in the trial—why will these measures show change? Present info in clear format for FAQs, ex.: travel expenses, risks, disclosure What are the side effects, benefits How will participation affect or be affected by my current medications? Concealment/placebo affects
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Roadblocks
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Sacrifices Time Money Confidentiality Ultimately, choosing and giving up one drug trial for another.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Roadblocks for Clinical Researchers Picking the right drugs. Designing the trial properly—number of patients, measures/biomarkers, length of study, placebo, how many sites. Getting the FDA to agree. Getting funding. Finding sites and getting them approved. Finding subjects. Doing the work in a timely fashion.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together PRO’S AND CON’S OF CANDIDATE DRUGS FOR HUMAN TRIALS Rationale--do we expect it to work? Basic Science Efficacy-has it worked in well-designed animal or pilot human trials? Safety-has safety been proven? Do the anticipated benefits outweigh the possible risks? Availability--designer drugs vs. already available ones. What’s in it for the drug company? Cost (and where to get the money from)
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together OFFICIAL PIPELINE FOR NEW DRUGS Up to 15 years and $ million to get to market Discovery—clinicians and scientists working out the cause of the disease, the “dominos” that fall over, and targeted candidate drugs. Preclinical testing—test tube and animal studies. Phase I—dosing, safety Phase II—safety, possible efficacy Phase III—efficacy FDA Approval Phase IV--Post-marketing studies for long-term side-effects and good effects. To help with promising drugs for serious diseases with unmet needs: NIH—Rapid Access to Intervention Development (RAID) FDA—Orphan Drug Status
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together FUNDING A PUBLIC-PRIVATE PARTNERSHIP Discovery—clinicians and scientists working out the cause of the disease, the “dominos” that fall over, and targeted candidate drugs. $25-80,000 per yr over many years Preclinical testing—test tube and animal studies. $100,000 per year for at least 2 yr Phase I and Phase II-- $ ,000 per year for 4 yr $2-4 million to get to this point Phase III—$4-5 million ($10K/subject) FDA Approval Post-marketing studies for long- term side-effects and good effects and possible other uses of the drug. Government Private research foundations Government Private research foundations Pharmaceutical companies Government Private research foundations Pharmaceutical companies
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together EFFICACY--CAN WE SHOW THAT THE DRUG ACTUALLY MAKES A DIFFERENCE? Symptomatic benefit vs. disease-modifying Is the candidate drug strong and specific? How much does the disease change over how much time? Natural history. How accurately can this change be measured? Rating scales, QOL measures. Can biomarkers show clinically meaningful change quicker? 1° vs. 2° outcome measure. Can enough researchers and patients be found? Research centers and registries.
March 17, 2011NAF AMM LA CA Bringing the Ataxia World Together Diagnostic (motor) threshold Model for Clinical Trials